TELA Bio is a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions. Co.'s main product, the OviTex Reinforced Tissue Matrix (OviTex), addresses needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials. Co. has designed an OviTex product for use in laparoscopic and robotic-assisted surgery called OviTex LPR. Co.'s other product, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses needs in plastic and reconstructive surgery. Co.'s OviTex PRS portfolio is supported by non-human primate data that demonstrated tissue integration and tissue remodeling. The TELA stock yearly return is shown above.
The yearly return on the TELA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TELA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|